MARKET

BCDA

BCDA

Biocardia Inc
NASDAQ
0.9011
-0.0199
-2.16%
Opening 12:27 10/26 EDT
OPEN
0.9300
PREV CLOSE
0.9210
HIGH
0.9300
LOW
0.8699
VOLUME
93.91K
TURNOVER
--
52 WEEK HIGH
1.800
52 WEEK LOW
0.7500
MARKET CAP
13.64M
P/E (TTM)
-1.1790
1D
5D
1M
3M
1Y
5Y
1D
BioCardia announces FDA acceptance of Helix pre-submission package
TipRanks · 10/19 13:41
BioCardia Advances Helix Catheter Toward FDA Clearance
TipRanks · 10/19 13:38
Weekly Report: what happened at BCDA last week (1012-1016)?
Weekly Report · 10/19 09:49
Weekly Report: what happened at BCDA last week (1005-1009)?
Weekly Report · 10/12 09:52
BioCardia Advances CardiAMP HF II Heart Failure Trial
TipRanks · 10/07 13:33
Weekly Report: what happened at BCDA last week (0928-1002)?
Weekly Report · 10/05 09:51
BioCardia Submits Revised FDA De Novo for Helix
TipRanks · 10/01 13:50
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
Barchart · 10/01 08:15
More
About BCDA
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

Webull offers BioCardia Inc stock information, including NASDAQ: BCDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCDA stock methods without spending real money on the virtual paper trading platform.